Status:
COMPLETED
Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)
Lead Sponsor:
Barbara Ann Karmanos Cancer Institute
Conditions:
Colorectal Cancer
Cancer of Pancreas
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this research study is for the participant to give their own T cells (a type of blood cell in the body that can fight infections and possibly cancer) to them after they have been remove...
Detailed Description
The purpose of this study is to determine in a dose-escalation phase Ib trial the safety of 3 infusions of EGFR2Bi armed activated T cells (aATC), after chemotherapy, for patients with advanced colore...
Eligibility Criteria
Inclusion
- Histological or cytological proof of colorectal or pancreatic adenocarcinoma
- Must have metastatic colorectal cancer or pancreatic cancer with stable disease after first line chemotherapy or patients with colorectal or pancreatic cancer who have progressed with standard chemotherapy options\*
- Standard chemotherapy for metastatic colorectal cancer include 5-FU/capecitabine with either oxaliplatin or irinotecan based regimen with or without bevacizumab or cetuximab.
- Standard chemotherapy for metastatic pancreatic cancer include gemzar based regimen or FOLFIRINOX (5-FU, oxaliplatin, and irinotecan)
- Prior cetuximab, panitumumab, or other monoclonal antibody therapy allowed if given 28 days prior to the 1st infusion of armed T cells
- Absolute Neutrophil Count (ANC) ≥ 1,000/mm3
- Lymphocyte count ≥ 400/mm3
- Platelet Count ≥ 50,000/mm3
- Hemoglobin ≥ 8 g/dL
- Serum Creatinine \< 2.0 mg/dl, Creatinine Clearance ≥50 ml/mm (can be calculated)
- Total Bilirubin ≤ 2 mg/dl (biliary stent is allowed)
- SGPT and SGOT \< 5.0 times normal
- LVEF ≥ 45% at rest (MUGA or Echo)
- Pulse Oximetry of \>88%
- Age ≥ 18 years at the time of consent
- Written informed consent and HIPAA authorization for release of personal health information
- Females of childbearing potential, and males, must be willing to use an effective method of contraception
- Females of childbearing potential must have a negative pregnancy test within 7 days of being registered for protocol therapy
- KPS ≥ 70% or SWOG Performance Status 0 or 1
Exclusion
- Any chemotherapy related toxicities from prior treatment.(\> grade I per CTCAE v4.0
- Known hypersensitivity to cetuximab or other EGFR antibody
- Treatment with any investigational agent within 14 days prior to being registered for protocol therapy Protocol version: 07/13/2011 8
- Symptomatic brain metastasis
- Chronic treatment with systemic steroids or another immuno-suppressive agent
- Serious non-healing wound, ulcer, bone fracture, major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to being registered for protocol therapy
- Active liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis
- HIV infection
- Positive HbsAg
- Positive Hepatitis C
- Active bleeding or a pathological condition that is associated with a high risk of bleeding
- Uncontrolled systemic disease like active infections
- Nonmalignant medical illnesses that are uncontrolled or a controlled illness that may be jeopardized by the treatment with protocol therapy
- Females must not be breastfeeding
- Patient may be excluded if, in the opinion of the PI and investigator team, the patient is not capable of being compliant
- Minor changes from these guidelines will be allowed at the discretion of the attending team under special circumstances. The reasons for exceptions will be documented.
Key Trial Info
Start Date :
August 17 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 19 2020
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT01420874
Start Date
August 17 2011
End Date
October 19 2020
Last Update
May 6 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States, 48601